2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Profiling, Treatment Considerations, Biological Therapies, (CAR)-T Cell Therapies, Artificial Intelligence (AI), Machine Learning, Biological Processes, CHIP, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Study Population, Human, Adult
PAPER

2105 Beyond BTK and PLCG2: Multi-omic profiling uncovers novel non-canonical pathways in BTKi-resistant CLL

Daniel Bihnam, MS, Daniela Trujillo Loaiza, MD2, Katie Stuart3, Sarah Davidov4, Laura Bruins5, Sutapa Sinha, PhD6, Zhiquan Wang, Ph.D7, Paul J. Hampel, MD8, Saad Kenderian, M.B., Ch.B.9, Neil E Kay, M.D.10, Sameer A. Parikh, MBBS11, Esteban Braggio, PhD12
1 Mayo Clinic Hospital, Phoenix, United States
2 Larkin Community Hospital, Miami, United States
3 ASU, Phoenix, United States
4 Mayo Clinic Hospital, Phoenix, United States
5 Mayo Clinic Hospital, Phoenix, United States
6 Mayo Clinic Hospital, Phoenix, Arizona, United States
7 Mayo Clinic Hospital, Rochester, United States
8 Mayo Clinic Hospital, Rochester, United States
9 Mayo Clinic Hospital, Rochester, United States
10 Mayo Clinic Hospital, Rochester, United States
11 Mayo Clinic Hospital, Rochester, United States
12 Mayo Clinic Hospital, Phoenix, Arizona, United States

Introduction: Bruton's tyrosine kinase inhibitors (BTKi) have transformed the treatment landscape of chronic lymphocytic leukemia (CLL); however, disease progression remains a major challenge. While approximately half of BTKi-resistant cases acquires BTK and/or PLCG2 mutations, the remaining patients exhibit alternative mechanisms of resistance that are incompletely understood. To investigate novel mechanisms of resistance, we performed a comprehensively genomic and transcriptomic screening in a cohort of CLL patients with disease progression following BTKi therapy but did not acquire BTK or PLCG2 mutations.

Materials and Methods: We identified 20 CLL patients, with disease progression on a covalent BTKi and do not have mutations in BTK or PLCG2 and compared the results with a cohort of 22 patients with BTK and/or PLCG2 mutations. Blood samples were collected baseline (before BTKi therapy) and at disease progression from BTKi (Ibrutinib/Acalabrutinib). The CD5+/CD19+ tumor population was enriched by flow sorting. We performed whole genome sequencing (WGS) in tumor/germline pairs with an average sequencing depth of 60X. Copy number variants (CNVpytor), structural variants – SV (Manta and DELLY2), single nucleotide variants (SNV) and indels (MuTect2, Strelka) were calculated. RNAseq was performed in the same samples. Differential gene expression analysis was performed using DESeq2 comparing paired baseline and progression samples from BTK/PLCG2 unmutated patients. Genes were ranked by Wald statistics and subjected to Gene Set Enrichment Analysis (GSEA) using Hallmark, KEGG, Reactome, and Gene Ontology databases. Differentially expressed genes were defined using an adjusted P < 0.05 and |log2 fold change| ≥1.

Results: The patients had a median of 4.5 lines of prior therapies (range 1 to 9). The median follow-up between the start of BTKi and disease progression was 3.04 years (range 0.17 – 9.33 years), compared with 4.8 years (1.17-10.67 years) in cases with BTK/PLCG2 mutations. IGHV unmutated was observed in 90% of cases, and 75% were male. At disease progression, del17p and/or TP53 mutations were found in 14 (70%) cases (8 with biallelic abnormalities), compared with 36% in mutated cases (3 biallelic). Deletions of 13q, 9p and 8p were found in 50%, 30% and 25% of cases, respectively. Commonly mutated genes were SF3B1 (25%), KRAS (20%) and XPO1 (15%). Notably, mutations in the RAS pathway (KRAS, NRAS, BRAF) were found in 50% cases, compared with 14% in mutated cases and mutations in chromatin modifiers genes in 45% cases (in both groups). Complex karyotype, defined as >3 copy number abnormalities, was found in 65% and chromothripsis in 20% cases (50% and 14% in mutated cases, respectively). Recurrent noncoding variants were found in regulatory regions (promoters, UTRs, enhancers and super-enhancers) of NFATC1, TNFRSF1B and BTG2. Analyzing the mutational signatures, we found enrichment of signatures associated with defective DNA mismatch repair (SBS44), homologous and nucleotide excision repair deficiency (SBS8), and indirect effects of AID-induced somatic mutagenesis (SBS85). Comparing samples at baseline and disease progression, 142 differentially expressed genes were identified, including 25 upregulated and 117 downregulated genes at disease progression. Progression was characterized by activation of inflammatory and proliferative programs, including TNFα signaling via NF-κB, G2/M checkpoint, E2F, MYC, and mTORC1 signaling, together with marked enrichment of ribosomal biogenesis, RNA processing, spliceosomal activity, and protein translation pathways. Additionally, progression was associated with suppression of B-cell receptor signaling, interferon signaling, cytokine signaling, and lymphocyte activation.

Conclusions: Disease progression of CLL on BTKi confirmed the existence of multiple driver genes beyond BTK, PLCG2, including the high prevalence of mutations in RAS pathway and epigenetic regulators, and increased genomic complexity. Furthermore, our findings suggest that BTKi resistance is driven by coordinated activation of multiple adaptive biological programs rather than a single compensatory signaling pathway and identify candidate pathways that may represent therapeutic vulnerabilities in patients lacking canonical resistance mutations.

Daniela Trujillo Loaiza, MD: No relevant conflicts of interest to declare.